EUVIMEDScopri EUVIMED
Multizentrische Studie

Clinical Implications of Subclinical Left Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Study

Masatoshi Minamisawa, Riccardo M Inciardi, Brian Claggett, Maja Cikes, Li Liu, Narayana Prasad, Tor Biering-Sørensen, Carolyn S P Lam, Sanjiv J Shah, Michael R Zile, Eileen O'Meara, Margaret M Redfield and 3 more

European Journal of Heart Failure · 2024-04-01 · 26 (4) · 871-881

DOI: 10.1002/ejhf.3167 ↗

At a glance

Multizentrische Studie in European Journal of Heart Failure, published online on 2024-02-18. Written by Masatoshi Minamisawa and 14 co-authors. Institution: Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Major MEDLINE topics: Heart Failure, Stroke Volume, Ventricular Dysfunction, Left, Valsartan. Cited 19 times so far (Crossref); 28 references. Funded by: Novartis, NIH/NHLBI, National Heart, Lung, and Blood Institute.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Aims

Left ventricular (LV) subclinical impairment has been described in heart failure with preserved ejection fraction (HFpEF). We assessed the relationship between LV myocardial deformation by strain imaging and recurrent hospitalization for heart failure (HF) or cardiovascular death in a large international HFpEF population. Methods and results We assessed two-dimensional speckle-tracking based global longitudinal strain (GLS) in 790 patients (mean age 74 ± 8 years, 54% female) with adequate image quality enrolled in the PARAGON-HF echocardiography study. We examined the relationship of GLS with total HF hospitalizations and cardiovascular death (the primary composite outcome) after accounting for clinical confounders. Approximately 47% of the population had evidence of LV subclinical dysfunction, defined as absolute GLS <16%. Impaired GLS was significantly associated with higher values of circulating baseline N-terminal pro-B-type-natriuretic peptide. After a median follow-up of 3.0 years, there were 407 total HF hospitalizations and cardiovascular deaths. After multivariable adjustment, worse GLS was associated with a greater risk for the primary composite outcome (adjusted hazard ratio per 1% decrease: 1.06; 95% confidence interval 1.02–1.11; p = 0.008). GLS did not modify the treatment effect of sacubitril/valsartan compared with valsartan for the composite outcome (p for interaction >0.1).

Conclusions

In a large HFpEF population, impaired LV function was observed even among patients with preserved ejection fraction, and was associated with an increased risk of total HF hospitalizations or cardiovascular death, accounting for clinical confounders. These findings highlight the key role of subtle LV systolic impairment in the pathophysiology of HFpEF.

Subjects

MeSH terms (MEDLINE)

Heart FailureStroke VolumeVentricular Dysfunction, LeftValsartanEchocardiographyHospitalizationHumansFemaleMaleAgedAminobutyratesBiphenyl CompoundsTetrazolesNatriuretic Peptide, BrainPeptide FragmentsAngiotensin Receptor AntagonistsPrognosisHeart VentriclesAged, 80 and overDrug Combinations

Author keywords

Heart failure with preserved ejection fractionPrognosisStrain

Substances

ValsartanAminobutyratesBiphenyl Compoundssacubitril and valsartan sodium hydrate drug combinationTetrazolesNatriuretic Peptide, BrainPeptide FragmentsAngiotensin Receptor Antagonistspro-brain natriuretic peptide (1-76)Drug Combinations

Authors and institutions

  • Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Department of Cardiovascular Medicine, Shinshu University School of Medicine, Matsumoto, Japan.
  • ASST Spedali Civili di Brescia and Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
  • Department for Cardiovascular Diseases, University of Zagreb School of Medicine and University Hospital Centre Zagreb, Zagreb, Croatia.
  • Department of Cardiology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark.
  • Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Funding

  • Novartis
  • NIH/NHLBI
  • National Heart, Lung, and Blood Institute

Cite

APA

Minamisawa, M., Inciardi, R. M., Claggett, B., Cikes, M., Liu, L., Prasad, N., Biering-Sørensen, T., Lam, C. S. P., Shah, S. J., Zile, M. R., O'Meara, E., Redfield, M. M., McMurray, J. J. V., Solomon, S. D., & Shah, A. M. (2024). Clinical Implications of Subclinical Left Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Study. European Journal of Heart Failure, 26(4), 871-881. https://doi.org/10.1002/ejhf.3167

Vancouver

Minamisawa M, Inciardi RM, Claggett B, Cikes M, Liu L, Prasad N, et al. Clinical Implications of Subclinical Left Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Study. European Journal of Heart Failure. 2024;26(4):871-881. doi:10.1002/ejhf.3167

BibTeX
@article{Minamisawa2024,
  author = {Minamisawa, Masatoshi and Inciardi, Riccardo M and Claggett, Brian and Cikes, Maja and Liu, Li and Prasad, Narayana and Biering-Sørensen, Tor and Lam, Carolyn S P and Shah, Sanjiv J and Zile, Michael R and O'Meara, Eileen and Redfield, Margaret M and McMurray, John J V and Solomon, Scott D and Shah, Amil M},
  title = {Clinical Implications of Subclinical Left Ventricular Dysfunction in Heart Failure with Preserved Ejection Fraction: The PARAGON-HF Study},
  journal = {European Journal of Heart Failure},
  year = {2024},
  volume = {26},
  number = {4},
  pages = {871--881},
  doi = {10.1002/ejhf.3167}
}
Start for free →